phentolamine mesylate · Famygen Life Sci · NDA 217064
Ryzumvi
Earliest generic entry, as listed
25 Oct 2039
Blocked by patent: US 11400077, US 12201615, US 12201616, US 12576066, US 12576067. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 13 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11400077 | use U-3804 · sets the listed date | 25 Oct 2039 |
| US 12201615 | use U-3804 · sets the listed date | 25 Oct 2039 |
| US 12201616 | use U-3804 · sets the listed date | 25 Oct 2039 |
| US 12576066 | use U-3804 · sets the listed date | 25 Oct 2039 |
| US 12576067 | use U-3804 · sets the listed date | 25 Oct 2039 |
| US 10278918 | drug product | 31 Jan 2034 |
| US 10772829 | drug product | 31 Jan 2034 |
| US 11090261 | drug product | 31 Jan 2034 |
| US 11844858 | drug product | 31 Jan 2034 |
| US 12350366 | drug product | 31 Jan 2034 |
| US 12721810 | drug product | 31 Jan 2034 |
| US 12734126 | use U-4604 | 31 Jan 2034 |
| US 9795560 | drug product | 31 Jan 2034 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217064 · 001 · RLD | solution, ophthalmic | EQ 0.75% BASE | 25 Oct 2039 |
Expired or delisted (1)
- NP · 25 Sep 2026